会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 4. 发明公开
    • 신규한 항균성 화합물
    • 具有抗微生物活性的新化合物
    • KR1020140107993A
    • 2014-09-05
    • KR1020130022330
    • 2013-02-28
    • 한국생명공학연구원
    • 김원곤김녕권윤주
    • C07D311/94C07D311/80A61K31/352A61P31/04
    • C07D311/94A61K31/352C07D311/80
    • The present invention relates to an antibiotic compound, and more particularly, to a novel compound exhibiting an antibiotic activity, an isomer thereof or a pharmaceutically acceptable salt thereof; an extract of the Penicillium sp. strain containing the compound; a fraction of the extract; an antibiotic composition containing the compound, the isomer thereof, or the pharmaceutically acceptable salt thereof as an active ingredient; a pharmaceutical composition for treating food poisoning; a pharmaceutical composition for preventing or treating septicemia; a pharmaceutical composition for preventing or treating pyogenic infection; a composition for inhibiting activity of FabI which is an enoyl-ACP reductase; and a method for preparing the composition. The compound of the present invention exhibits antibacterial activities of suppressing the growth of Staphylococcus aureus, Bacillus, and vancomycin-resistant enterococcus by inhibiting the activity of the enoyl-ACP reductase, and thus can be widely used for the development of a medicine for preventing or treating food poisoning, septicemia, or pyogenic infection.
    • 本发明涉及一种抗生素化合物,更具体地说涉及一种具有抗生素活性的新化合物,其异构体或其药学上可接受的盐; 青霉属的提取物 含有化合物的菌株; 一部分提取物; 含有化合物,其异构体或其药学上可接受的盐作为活性成分的抗生素组合物; 用于治疗食物中毒的药物组合物; 用于预防或治疗败血症的药物组合物; 用于预防或治疗化脓感染的药物组合物; 用于抑制作为烯酰基-ACP还原酶的FabI的活性的组合物; 以及制备该组合物的方法。 本发明的化合物通过抑制烯酰-ACP还原酶的活性而显示出抑制金黄色葡萄球菌,芽孢杆菌和万古霉素耐药性肠球菌生长的抗菌活性,因此可广泛用于开发用于预防或 治疗食物中毒,败血病或化脓感染。
    • 5. 发明公开
    • 에노일 리덕테이즈 저해 및 항균 활성을 갖는 신규한 히스피딘계 화합물
    • 具有ENOYL-ACP还原抑制作用和抗生素活性的新型HISPIDIN型化合物
    • KR1020120072931A
    • 2012-07-04
    • KR1020100134865
    • 2010-12-24
    • 한국생명공학연구원
    • 김원곤권윤주손미진
    • A61K31/34A61K31/366A61P31/04A61P31/00
    • A61K31/34A61K31/366
    • PURPOSE: An antibacterial composition containing novel hispidin-based compounds is provided to suppress Fab I and Fab k enzyme activities and to ensure strong antibacterial function. CONSTITUTION: An antibacterial composition contains a compound of chemical formula 1 or 2, isomer thereof, derivative, or pharmaceutically acceptable salt thereof. The compound is prepared from Phellinus linteus 08090-29 strain. The composition has an antibacterial function from Staphylococus aureus, Bacillus subtili, Staphylococcus epidermis, methicillin-resistant Staphylococcus aureus(MRSA), quinolone-resistant Staphylococcus aureus(QRSA), or Streptococcus pneumonia. A composition for suppressing enoyl reductase contains the compound of chemical formula 1 or 2. An antibacterial quasi-drug composition contains the composition as an active ingredient.
    • 目的:提供含有新的基于啶啶类化合物的抗菌组合物,以抑制Fab I和Fab k酶的活性并确保强的抗菌功能。 构成:抗菌组合物含有化学式1或化合物2,其异构体,衍生物或其药学上可接受的盐。 该化合物由Ponyinus linteus 08090-29菌株制备。 该组合物具有金黄色葡萄球菌,枯草芽孢杆菌,表皮葡萄球菌,耐甲氧西林金黄色葡萄球菌(MRSA),喹诺酮耐药金黄色葡萄球菌(QRSA)或肺炎链球菌的抗菌功能。 用于抑制烯酰基还原酶的组合物含有化学式1或化合物2.抗菌准药物组合物含有组合物作为活性成分。
    • 6. 发明授权
    • 펩타이드 디포밀레이즈 저해 및 항균활성을 갖는 신규후미마이신 화합물
    • 新的富马酸化合物与肽的缺陷酶抑制活性和抗微生物活性
    • KR100862645B1
    • 2008-10-09
    • KR1020070048677
    • 2007-05-18
    • 한국생명공학연구원
    • 김원곤권윤주정창길
    • C07D307/84A61K31/343
    • A novel fumimycin compound is provided to show excellent inhibitory activity on peptide deformylase(PDF), thereby exhibiting antibacterial activity on Staphylococcus aureus, methicillin resistant Staphylococcus aureus(MRSA) or quinolone-resistant Staphylococcus aureus(QRSA). A compound having the PDF inhibitory and antimicrobial activity is represented by a formula(1). A pharmaceutical composition having the antimicrobial activity on S. aureus, MRSA or QRSA comprises the compound of the formula(1) as an effective ingredient. An Aspergillus fumisynnematus F746 producing the compound of the formula(1) is deposited as a deposition no. KCTC 11090BP.
    • 提供了一种新颖的富马酸化合物,以显示出对肽脱甲酰酶(PDF)的优异抑制活性,从而对金黄色葡萄球菌,耐甲氧西林金黄色葡萄球菌(MRSA)或喹诺酮耐药金黄色葡萄球菌(QRSA)表现出抗菌活性。 具有PDF抑制和抗微生物活性的化合物由式(1)表示。 具有对金黄色葡萄球菌,MRSA或QRSA的抗微生物活性的药物组合物包含式(1)的化合物作为有效成分。 产生式(1)化合物的烟曲霉F746作为沉积物沉积。 KCTC 11090BP。
    • 7. 发明公开
    • 펩티드 디포밀라제 저해 및 항균 활성을 갖는 신규한 프라비마이신 화합물
    • 具有肽变态抑制和抗细菌活性的新型FLAVIMYCIN化合物
    • KR1020120079281A
    • 2012-07-12
    • KR1020110000491
    • 2011-01-04
    • 한국생명공학연구원
    • 김원곤권윤주손미진
    • A61K31/343C07D307/87C12P17/16C12R1/66
    • C07D307/87C12P17/162C12R1/66A61K31/343
    • PURPOSE: A novel flavimycin compound and an antibacterial composition containing the same are provided to treat infectious diseases by superbacteria. CONSTITUTION: An antibacterial composition contains a compound of chemical formula 1 or 2, or isomer, derivative, or pharmaceutically acceptable salt thereof. The compound is prepared from Aspergillus flavipes F020543 strain(KCTC 10880BP). The composition has an antibacterial activity against Staphylococus aureus, Bacillus subtilis, Staphylococcus epidermis, methicillin-resistant Staphylococcus aureus(MRSA), or quinolone-resistant Staphylococcus aureus(QRSA). A composition for suppressing peptide diformylase activity contains the compound of chemical formula 1 or 2. A method for preparing the compound of chemical formula 1 or 2 comprises: a step of culturing Aspergillus flavipes F020543 strain(KCTC 10880BP) or mutant strain thereof; a step of extracting the strain culture liquid and mycelium with an organic solvent; and a step of performing chromatography of the ethyl acetate extract.
    • 目的:提供一种新型的黄霉素化合物和含有此类抗生素的抗菌组合物,以通过超细菌治疗感染性疾病。 构成:抗菌组合物含有化学式1或化合物2或其异构体,衍生物或药学上可接受的盐。 该化合物由黄曲霉F020543菌株(KCTC 10880BP)制备。 该组合物对金黄色葡萄球菌,枯草芽孢杆菌,表皮葡萄球菌,耐甲氧西林金黄色葡萄球菌(MRSA)或喹诺酮耐药金黄色葡萄球菌(QRSA)具有抗菌活性。 用于抑制肽二糖酶活性的组合物含有化学式1或化合物2.化学式1或化合物2的制备方法包括:培养黄曲霉F020543菌株(KCTC 10880BP)或其突变菌株的步骤; 用有机溶剂提取菌株培养液和菌丝体的步骤; 以及进行乙酸乙酯提取物的层析的步骤。
    • 10. 发明公开
    • 폴리사이클릭 펩타이드 화합물을 포함하는 항균용 조성물 및 이의 생산방법
    • 包含多环磷酸酯化合物的抗菌组合物及其生产方法
    • KR1020120079455A
    • 2012-07-12
    • KR1020120001231
    • 2012-01-04
    • 한국생명공학연구원
    • 김원곤권윤주손미진
    • C12N1/20A61K35/74
    • A01N43/90A61K31/404C07K7/06
    • PURPOSE: A Streptomyces sp. AN1542 strain having an antibacterial activity and a compound using the same are provided to enhance antibacterial effect against MRSA, QRSA, VRSA and VRE and to treat infectious diseases. CONSTITUTION: A Streptomyces sp. AN1542 strain(deposit number:KCTC 12113BP) has an antibacterial effect. An antibacterial composition contains a compound of chemical formula 1 or 2 or isomer, derivative, or pharmaceutically acceptable salt thereof, a strain producing the compounds, spore thereof, bacteria body, or culture thereof. The composition is a pharmaceutical or quasi-drug composition. A method for preparing the compound or isomer, derivative, or pharmaceutically acceptable salt thereof comprises: a step of culturing the strain or mutant strain; a step of extracting the culture and mycelium of the strain with an organic solvent to obtain ethyl acetate; and a step of performing chromatography to the ethyl acetate extract.
    • 目的:链霉菌属 提供具有抗菌活性的AN1542菌株和使用其的化合物,以增强对MRSA,QRSA,VRSA和VRE的抗菌作用,并治疗感染性疾病。 构成:链霉菌属 AN1542菌株(保藏号:KCTC 12113BP)具有抗菌作用。 抗菌组合物含有化学式1或化合物2或其异构体,衍生物或药学上可接受的盐,产生化合物,其孢子,细菌体或其培养物的菌株。 该组合物是药物或准药物组合物。 制备化合物或其异构体,衍生物或其药学上可接受的盐的方法包括:培养菌株或突变菌株的步骤; 用有机溶剂提取菌株的培养物和菌丝体以获得乙酸乙酯的步骤; 以及对乙酸乙酯提取物进行色谱的步骤。